Share ownership WuXi Biologics (Cayman) Inc. OTC Markets

WXXW.Y

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2026-06-08 pm EDT			5-day change	1st Jan Change
7.780 ^USD	-4.89%		-11.59%	-2.75%

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE

Share class: WuXi Biologics (Cayman) Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,141,014,517	3,727,844,664 ( 90.02 %)	0	90.02 %

Major shareholders: WuXi Biologics (Cayman) Inc.

Name	Stocks	%	Valuation
RhumbLine Advisers LP 0.000466 %	9,643	0.000466 %	82 641 $
PNC Wealth Management LLC 0.000191 %	3,944	0.000191 %	33 800 $
Accent Capital Management LLC 0.000189 %	3,901	0.000189 %	33 432 $
Westside Investment Management LLC 0.000108 %	2,229	0.000108 %	19 103 $
GAMMA Investing LLC 0.000077 %	1,597	0.000077 %	13 686 $
IMA Advisory Services, Inc. 0.000001 %	24	0.000001 %	206 $

Name	Stocks	%	Valuation
Wuxi Biologics Holdings Ltd. 8.693 %	359,962,633	8.693 %	1 531 M $
BlackRock Fund Advisors 2.479 %	102,640,162	2.479 %	437 M $
BlackRock Advisors (UK) Ltd. 1.824 %	75,508,831	1.824 %	321 M $
ICBC UBS Asset Management Co. Ltd. 0.8717 %	36,097,444	0.8717 %	154 M $
China Asset Management Co., Ltd. 0.6126 %	25,367,000	0.6126 %	108 M $
BlackRock Investment Management (UK) Ltd. 0.6037 %	24,999,193	0.6037 %	106 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 0.5557 %	23,010,135	0.5557 %	98 M $
China Southern Asset Management Co., Ltd. 0.5077 %	21,024,000	0.5077 %	89 M $
Zhi Sheng Chen 0.4461 %	18,472,892	0.4461 %	79 M $
Aegon-Industrial Fund Management Co., Ltd. 0.4128 %	17,094,000	0.4128 %	73 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	13.05%
Others	8.69%
Individuals	0.62%
Unknown	77.64%

Based on 1000 largest holdings

Geographical origin of shareholders

British Virgin Islands	8.69%
China	5.87%
United States	2.96%
United Kingdom	2.63%
Hong Kong	0.68%
Individuals	0.62%
Netherlands	0.18%
Singapore	0.11%
Canada	0.11%
Japan	0.09%
Malaysia	0.07%
Italy	0.06%
Luxembourg	0.06%
Ireland	0.05%
France	0.04%
Australia	0.03%
Denmark	0.02%
Germany	0.02%
Switzerland	0.02%
Sweden	0.01%
Slovenia	0.01%
New Zealand	0.01%
South Africa	0.01%

Based on 1000 largest holdings

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

13,252

Sector

Biotechnology & Medical Research

More about the company